Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10280948 | 0.81 | GRIK1 (0.38) | GRIK1GRIK2CTSKDPP4DPP8 | |
| SCHEMBL19779250 | 0.76 | — | — | |
| SCHEMBL18515369 | 0.76 | — | — | |
| SCHEMBL18949541 | 0.76 | — | — | |
| SCHEMBL13711357 | 0.73 | — | — | |
| SCHEMBL13939159 | 0.73 | GRIK1 (0.31) | GRIK1GRIK2CTSK | |
| SCHEMBL13939155 | 0.73 | GRIK1 (0.33) | GRIK1GRIK2 | |
| SCHEMBL6722344 | 0.71 | — | — | |
| SCHEMBL27363123 | 0.71 | TDP1 (0.33) | — | |
| SCHEMBL11318678 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013028615-A2 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | S&T GOLBAL INC. (US) | 2013-02-28 | — | — | WO | disclosed |
| US-20120129789-A1 | COMPOSITIONS AND METHODS FOR HAIR GROWTH | YOELIN STEVEN (US) | 2012-05-24 | — | — | US | disclosed |
| US-20110092443-A1 | CYCLOSPORINE COMPOSITIONS FOR ENHANCING NAIL GROWTH | ALLERGAN, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-7902155-B2 | For treatment of mucin deficiency (dry mouth syndrome, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, oral mucosa cancer, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter plylori infection, ulcers, peptic ulcers, conditions affecting the uterus and appendicitis) | ALLERGAN, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100317595-A1 | COMPOSITIONS FOR ENHANCING NAIL GROWTH | ALLERGAN, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100279951-A1 | METHOD OF TREATING ALLERGIC CONJUNCTIVITIS WITH CYCLOSPORIN COMPOSITIONS | SAINT REGIS MOHAWK TRIBE | 2010-11-04 | — | — | US | disclosed |
| US-20100144609-A1 | METHODS USING CYCLOSPORIN IN TREATING PATIENTS WITH INTRAOCULAR LENSES | DONNENFELD ERIC D | 2010-06-10 | — | — | US | disclosed |
| US-7655625-B2 | Methods of treating blepharospasm using cyclosporine components | ALLERGAN, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-20090298753-A1 | METHODS FOR THE THERAPEUTIC USE OF CYCLOSPORINE COMPONENTS | ALLERGAN, INC. | 2009-12-03 | — | — | US | disclosed |
| US-7368426-B2 | Methods for the therapeutic use of cyclosporine components | ALLERGAN, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080076707-A1 | Methods for the therapeutic use of cyclosporine components | ALLERGAN, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076707-A1 | Methods for the therapeutic use of cyclosporine components | MALT1, FKBP5, FKBP1A | GRIK1 1852/4885GRIK2 2106/4885CTSK 803/4885 |
| US-20110092443-A1 | CYCLOSPORINE COMPOSITIONS FOR ENHANCING NAIL GROWTH | PIK3C3, NACA, TYR | GRIK1 4819/4885GRIK2 4855/4885CTSK 99/4885 |
| US-20100144609-A1 | METHODS USING CYCLOSPORIN IN TREATING PATIENTS WITH INTRAOCULAR LENSES | CRYAB, FKBP3, FKBP2 | GRIK1 4507/4885GRIK2 4476/4885CTSK 602/4885 |
| US-20100279951-A1 | METHOD OF TREATING ALLERGIC CONJUNCTIVITIS WITH CYCLOSPORIN COMPOSITIONS | TSLP, CHP1, MALT1 | GRIK1 2978/4885GRIK2 3015/4885CTSK 93/4885 |
| US-20120129789-A1 | COMPOSITIONS AND METHODS FOR HAIR GROWTH | CYP21A2, CYP2A7, PPP3R1 | GRIK1 4489/4885GRIK2 4442/4885CTSK 1801/4885 |
| US-20100317595-A1 | COMPOSITIONS FOR ENHANCING NAIL GROWTH | TYR, NACA, PIK3C3 | GRIK1 3556/4885GRIK2 4054/4885CTSK 169/4885 |
| US-20090298753-A1 | METHODS FOR THE THERAPEUTIC USE OF CYCLOSPORINE COMPONENTS | MALT1, FKBP3, FKBP5 | GRIK1 1728/4885GRIK2 2136/4885CTSK 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.